Oct 24 (Reuters) - Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.
Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.
The company, however, cut the top-end of its 2024 adjusted profit forecast to $14.70 per share from $14.90, due to an about 15 cent impact from weather-related disruptions, keeping the low-end at $14.30.
Analysts on average see profit for the period to be $14.56 per share, according to data compiled by LSEG.
The company's sales rose 7.4% to $3.28 billion from a year earlier, beating analysts' average estimate of $3.26 billion.
On an adjusted basis, Labcorp reported a third-quarter profit of $3.50 per share, above estimates of $3.48 per share.
(Reporting by Puyaan Singh in Bengaluru; Editing by Maju Samuel)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.